Related Experiment Video
Updated: May 18, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents
1Divisions of Pathology, Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA. mohammad.azam@cchmc.org
Abstract:
The discovery of oncogenes and tumor suppressors as a driver of cancer development has triggered the development of target-specific small molecule anticancer compounds. As exemplified by Imatinib (Gleevec), a specific inhibitor of the Chronic Myeloid Leukemia-associated BCR/ABL kinase, these agents promise impressive activity in clinical trials, with low levels of clinical toxicity. However, such therapy is susceptible to the emergence of drug resistance mainly due to amino acid substitutions in the target protein. Defining the spectrum of such mutations is important for patient monitoring and the design of next-generation inhibitors. Using Imatinib and BCR/ABL as a paradigm for a drug-target pair, we reported a retroviral vector-based screening strategy to identify the spectrum of resistance-conferring mutations, which has helped in designing the next-generation BCR/ABL inhibitors such as Nilotinib, Dasatinib, and Ponatinib. Here we provide a detailed methodology for the screen, which can be generally applied to any drug-target pair.
Insights
Target-specific cancer drugs show promise but face resistance from mutations. A new retroviral screening method identifies these resistance mutations, aiding the development of next-generation cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Target-specific small molecule anticancer compounds, like Imatinib, are effective but can lead to drug resistance.
- Drug resistance often arises from amino acid substitutions in the target protein, necessitating monitoring and new drug design.
Purpose of the Study:
- To develop and detail a retroviral vector-based screening strategy for identifying drug resistance mutations.
- To establish a generalizable methodology applicable to any drug-target pair for understanding resistance mechanisms.
Main Methods:
- Utilized a retroviral vector-based screening strategy.
- Employed Imatinib and BCR/ABL as a model drug-target system to validate the screening approach.
Main Results:
- Successfully identified a spectrum of BCR/ABL mutations conferring resistance to Imatinib.
- The screening strategy facilitated the design of next-generation BCR/ABL inhibitors, including Nilotinib, Dasatinib, and Ponatinib.
Conclusions:
- A retroviral screening method is effective for identifying drug resistance mutations.
- This methodology can be broadly applied to accelerate the development of novel therapeutics against various drug targets.
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
01:16In vitro Mutagenesis
01:16In-vitro Mutagenesis